Key cost components extracted from studies included in review (Adjusted to 2011 USD).*

*List is not a comprehensive list of all costs included in studies, but is restricted to those costs included in common decision model described in main text.N/A = Cost not included in study.Full LTBI tx cost = includes cost for complete regimen cited in publication.Active TB Cost = cost for a passively diagnosed Active case.IGRA test cost = All studies considered Quantiferon, except Reference (12) (T-Spot only), Reference (16) (generic IGRA) and Reference (20) (included both QFN and T-spot).**Cost is for drugs and incentives only. Administrative and delivery expenses associated with LTBI treatment are included in the fixed program costs of 150 US$ (2007) per year per study participant. These additional costs are not accounted for in any of the costs categories listed above.†Cost shown for mild hepatitis.* 本清单并非纳入所有研究的成本的完整汇总，仅限定于主文所述常见决策模型中纳入的成本范畴。N/A 表示该研究未纳入此项成本。完整潜伏性结核感染（LTBI, Latent Tuberculosis Infection）治疗成本：涵盖文献中提及的完整疗程相关费用。活动性结核（Active TB）成本：指被动确诊的活动性结核病例相关成本。干扰素γ释放试验（IGRA, Interferon-Gamma Release Assay）检测成本：所有研究均采用奎根菲诺（Quantiferon）检测，仅参考文献[12]仅采用T-Spot检测、参考文献[16]采用通用IGRA检测，以及参考文献[20]同时纳入奎根菲诺（QFN, Quantiferon）与T-Spot检测。** 本项成本仅包含药物与激励费用。与LTBI治疗相关的行政与执行成本，已纳入每位研究参与者每年150美元（2007年币值）的固定项目成本范畴，上述各类成本分类均未涵盖此项额外成本。† 所示成本为轻度肝炎相关费用。